[go: up one dir, main page]

PE20001387A1 - Compuestos empleados en el tratamiento de padecimientos inflamatorios - Google Patents

Compuestos empleados en el tratamiento de padecimientos inflamatorios

Info

Publication number
PE20001387A1
PE20001387A1 PE1999001274A PE00127499A PE20001387A1 PE 20001387 A1 PE20001387 A1 PE 20001387A1 PE 1999001274 A PE1999001274 A PE 1999001274A PE 00127499 A PE00127499 A PE 00127499A PE 20001387 A1 PE20001387 A1 PE 20001387A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
phenyl
amino
compound
Prior art date
Application number
PE1999001274A
Other languages
English (en)
Inventor
Duncan Robert Armour
David Brown
Miles Stuart Congreve
Paul Martin Gore
Darren Victor Steven Green
Peter Ward
Torquil Iain Maclean Jack
Steven Philip Keeling
Andrew Mcmurtrie Mason
Karen Morriss
Nigel Grahame Ramsden
Stuart Holman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20001387A1 publication Critical patent/PE20001387A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205Radicals derived from carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043Leu-amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 Y R2 SON ALQUILO C1-C6, CICLOALQUILO C3-C8, (CH2)e-Ar1, (CH2)eOAr1 O NR1R2 FORMAN PIRROLIDINILO, PIPERIDINILO, PIPERAZINILO, ENTRE OTROS; R3 ES ALQUILO C1-C6-NHC(=NH)NH2, ALQUENILO C2-C6-NHC(=NH)NH2, (CH2)c-2,4-IMIDAZOLIDINODIONA, (CH2)zDIBENZOFURANO, ENTRE OTROS; R4 ES H, ALQUILO C1-C6, ALQUILO C1-C3-CICLOALQUILO C3-C6, (CH2)qAr2, ALQUILO C1-C6-NR12R13, ENTRE OTROS; R5 ES H, JUNTO CON R4 Y C FORMAN CICLOALQUILO C5-C7; R6 ES H, ALQUILO C1-C6, JUNTO A R4 Y C O N FORMAN PIRROLIDINA; R7 ES H, (CH2)wNR12R13, (CH2)uAr2, (CH2)wNR12-COALQUILO C1-C6; R8, R9, R16 SON H, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; R12, R13 SON H, ALQUILO C1-C6; Ar1 ES FENILO, HETEROCICLO 5-6 MIEMBROS CON 1-3 O, N, S; Ar2 ES FENILO; c, z SON 0-2; u ES 1-2; e Y w SON 1-3. UN COMPUESTO PREFERIDO ES ACIDO (2S)-2-[((2S)-2-{[2-(2-BENZOILFENOXI)ACETIL]AMINO}-4-METILPENTANOIL)AMINO]-3-{4-[({4-[(2-FENILACETIL)AMINO]-1-PIPERIDINIL}CARBONIL)OXI}FENIL}PROPIONICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION, A COMPUESTOS INTERMEDIOS Y A UNA COMPOSICION QUE COMPRENDE ADEMAS A UN AGONISTA DEL RECEPTOR ADRENERGICO ß2. EL COMPUESTO DE FORMULA I ES UN ANTAGONISTA DE O4-INTEGRINA Y PUEDEN SER UTILES COMO AGENTES ANTIINFLAMATORIOS
PE1999001274A 1998-12-18 1999-12-16 Compuestos empleados en el tratamiento de padecimientos inflamatorios PE20001387A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9828074.6A GB9828074D0 (en) 1998-12-18 1998-12-18 Therapeutically useful compounds

Publications (1)

Publication Number Publication Date
PE20001387A1 true PE20001387A1 (es) 2000-12-22

Family

ID=10844608

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001274A PE20001387A1 (es) 1998-12-18 1999-12-16 Compuestos empleados en el tratamiento de padecimientos inflamatorios

Country Status (26)

Country Link
US (1) US6867192B1 (es)
EP (1) EP1140837B1 (es)
JP (1) JP4431282B2 (es)
KR (1) KR20010101258A (es)
CN (1) CN1330637A (es)
AR (1) AR023727A1 (es)
AT (1) ATE273954T1 (es)
AU (1) AU760169B2 (es)
BR (1) BR9916282A (es)
CA (1) CA2355630A1 (es)
CO (1) CO5170533A1 (es)
CZ (1) CZ20012209A3 (es)
DE (1) DE69919580T2 (es)
ES (1) ES2226488T3 (es)
GB (1) GB9828074D0 (es)
GT (1) GT199900217A (es)
HK (1) HK1038744A1 (es)
HU (1) HUP0104867A3 (es)
IL (1) IL142908A0 (es)
NO (1) NO20012995L (es)
NZ (1) NZ511478A (es)
PE (1) PE20001387A1 (es)
PL (1) PL348059A1 (es)
TR (1) TR200101709T2 (es)
WO (1) WO2000037444A1 (es)
ZA (1) ZA200103948B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1244656A1 (en) 1999-12-28 2002-10-02 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
GB0014947D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014883D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014881D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0014851D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014869D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014849D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0127423D0 (en) * 2001-11-15 2002-01-09 Glaxo Group Ltd Process
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
WO2004103967A2 (en) 2003-05-20 2004-12-02 Genentech, Inc. Thiocarbamate inhibitors of alpha-4 integrins
WO2005117978A2 (en) 2004-06-04 2005-12-15 Genentech, Inc. Method for treating multiple sclerosis
US8482496B2 (en) 2006-01-06 2013-07-09 Pixtronix, Inc. Circuits for controlling MEMS display apparatus on a transparent substrate
US9158106B2 (en) 2005-02-23 2015-10-13 Pixtronix, Inc. Display methods and apparatus
US7742016B2 (en) 2005-02-23 2010-06-22 Pixtronix, Incorporated Display methods and apparatus
US8519945B2 (en) 2006-01-06 2013-08-27 Pixtronix, Inc. Circuits for controlling display apparatus
US8159428B2 (en) 2005-02-23 2012-04-17 Pixtronix, Inc. Display methods and apparatus
US9261694B2 (en) 2005-02-23 2016-02-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US9229222B2 (en) 2005-02-23 2016-01-05 Pixtronix, Inc. Alignment methods in fluid-filled MEMS displays
US7999994B2 (en) 2005-02-23 2011-08-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US20070205969A1 (en) 2005-02-23 2007-09-06 Pixtronix, Incorporated Direct-view MEMS display devices and methods for generating images thereon
US9082353B2 (en) 2010-01-05 2015-07-14 Pixtronix, Inc. Circuits for controlling display apparatus
US8310442B2 (en) 2005-02-23 2012-11-13 Pixtronix, Inc. Circuits for controlling display apparatus
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US8526096B2 (en) 2006-02-23 2013-09-03 Pixtronix, Inc. Mechanical light modulators with stressed beams
US9176318B2 (en) * 2007-05-18 2015-11-03 Pixtronix, Inc. Methods for manufacturing fluid-filled MEMS displays
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
US8169679B2 (en) 2008-10-27 2012-05-01 Pixtronix, Inc. MEMS anchors
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
KR101798312B1 (ko) 2010-02-02 2017-11-15 스냅트랙, 인코포레이티드 디스플레이 장치를 제어하기 위한 회로
EP2531881A2 (en) 2010-02-02 2012-12-12 Pixtronix Inc. Methods for manufacturing cold seal fluid-filled display apparatus
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
AR091305A1 (es) 2012-01-31 2015-01-28 Genentech Inc ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
US9134552B2 (en) 2013-03-13 2015-09-15 Pixtronix, Inc. Display apparatus with narrow gap electrostatic actuators
BR112016028081A2 (pt) * 2014-05-30 2017-08-22 Sphaera Pharma Private Ltd Novos compostos como agentes antituberculares
EP3319639B1 (en) * 2015-07-08 2020-11-18 Axerovision, Inc. Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions
DK3359572T3 (da) 2015-10-06 2025-01-27 Hoffmann La Roche Fremgangsmåde til behandling af multipel sklerose
AU2017273857B2 (en) * 2016-06-01 2021-08-19 Athira Pharma, Inc. Compounds
CN109722455B (zh) * 2017-10-31 2022-03-11 中国科学院天津工业生物技术研究所 微生物发酵生产谷内酯的方法、工程菌及应用
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
CN112969504B (zh) 2018-10-30 2024-04-09 吉利德科学公司 用于抑制α4β7整合素的化合物
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
MX2021005050A (es) 2018-10-30 2021-06-15 Gilead Sciences Inc Derivados de quinolina como inhibidores de integrina alfa4beta7.
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
US20240158375A1 (en) * 2020-10-21 2024-05-16 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593858A1 (de) * 1967-03-02 1970-10-29 Hoechst Ag Verfahren zur Herstellung tyrosinhaltiger Peptide und deren Derivaten
US4105602A (en) * 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
EP1001764A4 (en) 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
JP2001517245A (ja) * 1997-05-29 2001-10-02 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのビアリールアルカン酸類
EP0998282A4 (en) * 1997-05-29 2000-08-30 Merck & Co Inc SULPHONAMIDES AS CELL ADHESION INHIBITORS
JP2002501518A (ja) 1997-05-30 2002-01-15 セルテック セラピューティックス リミテッド 抗炎症性チロシン誘導体

Also Published As

Publication number Publication date
HUP0104867A3 (en) 2002-06-28
AU760169B2 (en) 2003-05-08
NO20012995L (no) 2001-08-15
WO2000037444A1 (en) 2000-06-29
PL348059A1 (en) 2002-05-06
CZ20012209A3 (cs) 2001-09-12
AU3039100A (en) 2000-07-12
ZA200103948B (en) 2002-11-15
EP1140837A1 (en) 2001-10-10
JP4431282B2 (ja) 2010-03-10
AR023727A1 (es) 2002-09-04
CO5170533A1 (es) 2002-06-27
GT199900217A (es) 2001-06-09
IL142908A0 (en) 2002-04-21
DE69919580T2 (de) 2005-09-01
CN1330637A (zh) 2002-01-09
CA2355630A1 (en) 2000-06-29
JP2002533326A (ja) 2002-10-08
ES2226488T3 (es) 2005-03-16
BR9916282A (pt) 2001-10-02
NZ511478A (en) 2003-08-29
GB9828074D0 (en) 1999-02-17
HUP0104867A2 (hu) 2002-04-29
NO20012995D0 (no) 2001-06-15
TR200101709T2 (tr) 2001-12-21
ATE273954T1 (de) 2004-09-15
EP1140837B1 (en) 2004-08-18
HK1038744A1 (zh) 2002-03-28
US6867192B1 (en) 2005-03-15
KR20010101258A (ko) 2001-11-14
DE69919580D1 (de) 2004-09-23

Similar Documents

Publication Publication Date Title
PE20001387A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
ES2572980T3 (es) Combinación de inhibidores de la proteasa del VHC con un tensioactivo
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20040775A1 (es) DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2
PE20040780A1 (es) Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion
PE20030258A1 (es) Derivados de dolastatina con actividad antitumoral
PE20021004A1 (es) Derivados de piperidina como inhibidores de la ccr5
PE20070462A1 (es) Compuestos derivados de fenilaminopropanol
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
ECSP045317A (es) Piridinoilpiperidinas como agonistas de 5-ht1f
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
PE20040898A1 (es) Nuevos compuestos derivados de pirimidina
PE20020917A1 (es) Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato
PE20070593A1 (es) Compuestos pirrolopirimidina como inhibidores de syk
PE20011119A1 (es) Composiciones farmaceuticas de agonista/antagonista de estrogenos para el tratamiento de afecciones que responden a un aumento de testosterona
AR040500A1 (es) Inhibidores de cinasas
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
PE20080072A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
AR018915A1 (es) Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos
UY28101A1 (es) Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
MEP22508A (en) Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed